Omeros Corporation
$ 12.54
2.37%
16 Apr - close price
- Market Cap 902,832,000 USD
- Current Price $ 12.54
- High / Low $ 12.60 / 12.09
- Stock P/E N/A
- Book Value -1.69
- EPS -0.08
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -5.76 %
- 52 Week High 17.65
- 52 Week Low 2.95
About
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Analyst Target Price
$38.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-07 | 2024-08-07 | 2024-05-15 | 2024-03-26 | 2023-11-09 | 2023-08-09 | 2023-05-09 |
| Reported EPS | -0.5464 | -0.34 | -0.43 | -0.5408 | -0.55 | -0.64 | -0.97 | -0.63 | -0.15 | -0.6 | -0.59 | -0.54 |
| Estimated EPS | -0.5202 | -0.45 | -0.46 | -0.58 | -0.71 | -0.7 | -1.14 | -0.58 | -0.55 | -0.62 | -0.57 | -0.56 |
| Surprise | -0.0262 | 0.11 | 0.03 | 0.0392 | 0.16 | 0.06 | 0.17 | -0.05 | 0.4 | 0.02 | -0.02 | 0.02 |
| Surprise Percentage | -5.0365% | 24.4444% | 6.5217% | 6.7586% | 22.5352% | 8.5714% | 14.9123% | -8.6207% | 72.7273% | 3.2258% | -3.5088% | 3.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMER
2026-04-16 18:10:18
Omeros Corporation announced that the U.S. Centers for Medicare & Medicaid Services has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for its product, YARTEMLEA. This J-code will streamline billing and reimbursement for YARTEMLEA for patients covered by U.S. government programs and commercial payers, becoming effective on July 1, 2026.
2026-04-16 13:09:15
Omeros Corporation has secured a permanent Healthcare Common Procedure Coding System J-code (J1289) for its TA-TMA treatment, Yartemlea, effective July 1, 2026. This code will simplify billing and reimbursement for the drug, which is FDA-approved for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and children. Analysts project Omeros to turn profitable this year with strong buy ratings, and the company recently reported a significant Q4 2025 earnings beat.
2026-04-16 13:09:15
Omeros Corporation announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J1289) for YARTEMLEA, effective July 1, 2026. This J-code will streamline billing and reimbursement for the drug, which is the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The move is expected to reduce administrative burdens, support faster patient access, and provide more predictable reimbursement for healthcare providers.
2026-04-12 07:11:17
Omeros Corporation (NASDAQ:OMER) has received a "Moderate Buy" consensus rating from six brokerages, with an average 12-month price target of $40.33, significantly higher than its current share price of $11.49. The company recently reported a surprisingly strong quarterly EPS of $3.14, beating estimates, despite analysts forecasting a negative full-year EPS. Insider David J. Borges sold 30,000 shares, while institutional investors like Vanguard and UBS materially increased their holdings.
2026-04-11 06:39:39
This article provides news and financial updates for OMEROS CORP (NASDAQ: OMER). It highlights the company's current stock price, recent performance, and a report from 12 days prior detailing its Q4 2025 earnings, which were boosted by a major asset sale, and the launch of its first commercial product.
2026-04-11 06:10:00
Omeros (OMER) has garnered a consensus price target from Wall Street analysts suggesting a potential upside of 266.7%. While analyst price targets can be misleading, growing optimism regarding the company's earnings prospects and a Zacks Rank #1 (Strong Buy) rating indicate a potential upside for the stock. Investors should consider these factors in conjunction, not solely relying on price targets.
